Article

PON1 status of farmworker mothers and children as a predictor of organophosphate sensitivity.

Department of Genome Sciences, Division of Medical Genetics, University of Washington, Seattle, Washington 98195-7720, USA.
Pharmacogenetics and Genomics (Impact Factor: 3.45). 04/2006; 16(3):183-90. DOI: 10.1097/01.fpc.0000189796.21770.d3
Source: PubMed

ABSTRACT The objective was to determine PON1 status as a predictor for organophosphorus insecticide sensitivity in a cohort of Latina mothers and newborns from the Salinas Valley, California, an area with high levels of organophosphorus insecticide use. PON1 status was established for 130 pregnant Latina women and their newborns using a high-throughput two substrate activity/analysis method which plots rates of diazoxon (DZO) hydrolysis against rates of paraoxon (PO) hydrolysis. Arylesterase activity (AREase) was determined using phenylacetate as a substrate, allowing comparison of PON1 levels across PON1192 genotypes in mothers and children. Phenylacetate hydrolysis is not affected by the Q192R polymorphism. Among newborns, levels of PON1 (AREase) varied by 26-fold (4.3-110.7 U/ml) and among mothers by 14-fold (19.8-281.4 U/ml). On average, children's PON1 levels were four-fold lower than the mothers' PON1 levels (P<0.001). Average PON1 levels in newborns were comparable with reported hPON1 levels in transgenic mice expressing human PON1Q192 or PON1R192, allowing for prediction of relative sensitivity to chlorpyrifos oxon (CPO) and DZO. The predicted range of variability in sensitivity of mothers and children in the same Latino cohort was 65-fold for DZO and 131 to 164-fold for CPO. Overall, these findings indicate that many of the newborns and some of the mothers in this cohort would be more susceptible to the adverse effects of specific organophosphorus pesticide exposure due to their PON1 status. Of particular concern are exposures of pregnant mothers and newborns with low PON1 status.

1 Follower
 · 
79 Views
  • Source
    Environmental Health Perspectives 04/2015; 123(4):A79-80. DOI:10.1289/ehp.1409124R · 7.03 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Une nouvelle approche scientifique de l'impact des pesticides sur la santé exige l'élaboration d'une politique de prévention. d'Action contre les Pesticides (Pesticide Action Network (PAN)) est un réseau de plus de 600 organisations non gouvernementales, institutions et individus situés dans plus de 60 pays qui oeuvrent pour supprimer l'utilisation de pesticides chimiques dangereux, en faveur d'alternatives écologiquement saines. Cinq structures continentales autonomes en coordonnent les projets et les campagnes. Les actions de PAN Europe, l'une des structures fondée en 1987, sont gérées conjointement par PAN Germany et PAN UK. PAN Europe est composé d'organisations de consommateurs, de santé, de défense de l'environnement, de syndicats, de groupes de femmes, d'organisations travaillant à la promotion de l'agriculture durable ainsi que d'associations d'agriculteurs. Plus 50 organisations européennes sont partenaires de PAN Europe et notre campagne pour la Réduction de l'Utilisation des Pesticides en Europe (PURE) est soutenue par plus de 90 organisations dans 30 pays européens.: elliott-paneurope@pan-uk.org www.pan-europe.info L'Alliance pour la Santé et l'Environnement (Health and Environment Alliance) L'Alliance pour la Santé et l'Environnement est une organisation non gouvernementale internationale qui vise à améliorer la santé au moyen d'une politique publique privilégiant un environnement plus propre et plus sûr. Notre travail se base sur les conclusions fondamentales tirées de la science de l'hygiène de l'environnement qui a révélé que la dégradation du milieu naturel a un impact sur la santé qui se manifeste par une augmentation de diverses pathologies et d'un mauvais état de santé général de la population.HEAL représente un réseau diversifié de plus de 50 organisations de citoyens, patients, femmes, professionnels du secteur médical et écologistes à travers l'Europe et possède une grande expérience sur les questions touchant à l'environnement et à la santé. Notre vision est celle d'une planète saine pour des hommes en bonne santé.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: There is evidence that genetic factors influence the probability of comorbidity of tobacco use disorder (TUD) with mood disorders. This study was carried out to examine whether both TUD and mood disorders are associated with genetic biomarkers particularly paraoxonase 1 (PON1) status, polymorphisms of glutathione S-transferases (GSTs), such as GSTM1 and GSTT1, and the STIn 2 polymorphism of the serotonin transporter. PON1 status (Q192R polymorphism and PON1 plasmatic activity), GSTM1, GSTT1, and STin.2 genotypes and alleles were assayed in 4 mutually exclusive study groups, i.e., comorbid mood disorder and TUD (n=95); TUD without mood disorders (n=90); mood disorders but no TUD (n=62); and controls (never-smokers without mood disorders; n=113). Logistic regression analyses showed that comorbid mood disorders and TUD were associated with significantly lower PON1 activity, the STin2.10/10 genotype (protective) or the Stin2.12 allele (risk factor) and the GSTM1 and GSTT1 null genotypes (protective). These results show that comorbid mood disorders and TUD are associated with specific polymorphisms related to oxidative stress and serotonin pathways. Copyright © 2014. Published by Elsevier Ireland Ltd.
    Neuroscience Letters 11/2014; 585. DOI:10.1016/j.neulet.2014.11.002 · 2.06 Impact Factor

Preview

Download
0 Downloads
Available from